OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Commerce. All rights reserved.
Massachusetts facility will be dedicated to offering viral vector production services
Thermo Fisher Scientific, a contract development and manufacturing organization (CDMO), has expanded its cell and gene therapy (CGT) capabilities with the opening of its new viral vector manufacturing facility in Plainville, MA. The 300,000 square-foot, state-of-the-art site is expected to add approximately 300 jobs to support the development, testing, and manufacture of viral vectors, which are critical components in the development and commercialization of gene therapies.
The new current good manufacturing practice (cGMP)-compliant Plainville facility grows the company’s clinical and commercial viral vector capacity to six sites in the US and Europe. The site features sustainable construction design, flexible laboratory and production suites, adjacent warehousing, and office space, as well as the CDMO's advanced bioproduction and analytical instrumentation technologies.
“Plainville is an impressive addition to our pharma services network as we continue to invest and innovate cell and gene therapy services, products, and workflows,” says Marc N. Casper, chairman, president, and CEO of Thermo Fisher Scientific. “We are enabling our customers to speed their scientific discoveries in cell and gene therapy while also supporting their manufacturing needs, whether they are early in the development process or ready to transition to clinical or commercial scale.”
The new facility is part of an investment strategy to provide customers with fully integrated capabilities that connect the entire CGT value chain—from early development and clinical scale-up to commercial manufacturing.